 Andres Henao Martinez
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 32 | 7.380 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 21 | 4.460 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 27 | 3.750 |
Why?
| | Cryptococcosis | 6 | 2023 | 23 | 3.520 |
Why?
| | Opportunistic Infections | 4 | 2024 | 43 | 2.670 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 23 | 2.460 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 18 | 1.900 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 3 | 1.760 |
Why?
| | HIV Infections | 10 | 2024 | 2453 | 1.750 |
Why?
| | Travel | 6 | 2021 | 121 | 1.640 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.460 |
Why?
| | Cryptococcus | 2 | 2024 | 7 | 1.450 |
Why?
| | Immunocompromised Host | 6 | 2024 | 192 | 1.370 |
Why?
| | Anti-Bacterial Agents | 9 | 2025 | 1471 | 1.300 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.290 |
Why?
| | Humans | 104 | 2025 | 114045 | 1.260 |
Why?
| | Tuberculosis | 2 | 2022 | 241 | 1.220 |
Why?
| | Hospitalization | 7 | 2024 | 1762 | 1.220 |
Why?
| | Transients and Migrants | 3 | 2023 | 22 | 1.190 |
Why?
| | Candidemia | 2 | 2024 | 7 | 1.180 |
Why?
| | Cardiomyopathies | 2 | 2021 | 298 | 1.160 |
Why?
| | Yellow Fever | 3 | 2022 | 7 | 1.100 |
Why?
| | Bacteremia | 5 | 2023 | 160 | 1.080 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 150 | 1.050 |
Why?
| | Adult | 37 | 2025 | 30375 | 1.040 |
Why?
| | Candida | 2 | 2024 | 32 | 1.010 |
Why?
| | Glucocorticoids | 3 | 2024 | 526 | 1.010 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 125 | 1.000 |
Why?
| | Antifungal Agents | 8 | 2023 | 128 | 0.980 |
Why?
| | Clarithromycin | 1 | 2025 | 26 | 0.970 |
Why?
| | Risk Factors | 15 | 2024 | 8614 | 0.970 |
Why?
| | Macrolides | 1 | 2025 | 57 | 0.940 |
Why?
| | Parasitemia | 2 | 2015 | 9 | 0.930 |
Why?
| | Pneumocystis | 1 | 2024 | 6 | 0.920 |
Why?
| | Azithromycin | 1 | 2025 | 80 | 0.920 |
Why?
| | Mycoses | 1 | 2024 | 66 | 0.910 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2024 | 24 | 0.910 |
Why?
| | Male | 45 | 2025 | 55396 | 0.900 |
Why?
| | Nitroimidazoles | 1 | 2023 | 6 | 0.880 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.880 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 83 | 0.880 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 334 | 0.860 |
Why?
| | Myocarditis | 2 | 2016 | 93 | 0.860 |
Why?
| | Coronavirus Infections | 7 | 2020 | 326 | 0.850 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 30 | 0.850 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 115 | 0.840 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 184 | 0.820 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 33 | 0.820 |
Why?
| | Zoonoses | 2 | 2024 | 21 | 0.820 |
Why?
| | Anaphylaxis | 1 | 2025 | 144 | 0.800 |
Why?
| | Virus Diseases | 1 | 2024 | 195 | 0.800 |
Why?
| | Middle Aged | 24 | 2025 | 26605 | 0.760 |
Why?
| | Antigens, Fungal | 2 | 2024 | 23 | 0.760 |
Why?
| | Neglected Diseases | 1 | 2020 | 4 | 0.730 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 61 | 0.720 |
Why?
| | Hepatitis | 1 | 2020 | 45 | 0.710 |
Why?
| | United States | 19 | 2024 | 12137 | 0.700 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.690 |
Why?
| | Heart Aneurysm | 1 | 2019 | 8 | 0.680 |
Why?
| | Epidemics | 1 | 2020 | 66 | 0.670 |
Why?
| | Female | 36 | 2025 | 59324 | 0.660 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.660 |
Why?
| | Aneurysm, False | 1 | 2019 | 45 | 0.650 |
Why?
| | Hepatitis A | 1 | 2019 | 26 | 0.650 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 20 | 0.630 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 2 | 0.630 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 4 | 0.630 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 16 | 0.630 |
Why?
| | Skin | 3 | 2022 | 653 | 0.620 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 27 | 0.600 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 25 | 0.600 |
Why?
| | Fever | 2 | 2020 | 280 | 0.600 |
Why?
| | Gonorrhea | 1 | 2019 | 54 | 0.600 |
Why?
| | Renal Insufficiency | 1 | 2020 | 137 | 0.590 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 1 | 0.590 |
Why?
| | Dyspnea | 1 | 2019 | 212 | 0.590 |
Why?
| | Retrospective Studies | 12 | 2024 | 12521 | 0.590 |
Why?
| | Hand Dermatoses | 1 | 2017 | 7 | 0.590 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 71 | 0.580 |
Why?
| | Population Groups | 1 | 2018 | 55 | 0.580 |
Why?
| | Meningioma | 1 | 2018 | 76 | 0.580 |
Why?
| | Heart Failure | 2 | 2022 | 1958 | 0.580 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 86 | 0.580 |
Why?
| | Medically Uninsured | 1 | 2018 | 122 | 0.570 |
Why?
| | Osteomyelitis | 1 | 2019 | 105 | 0.570 |
Why?
| | Abscess | 1 | 2018 | 70 | 0.570 |
Why?
| | Pandemics | 10 | 2023 | 1310 | 0.570 |
Why?
| | Milk | 1 | 2018 | 123 | 0.550 |
Why?
| | Poliomyelitis | 3 | 2022 | 27 | 0.550 |
Why?
| | Latin America | 6 | 2022 | 68 | 0.550 |
Why?
| | Aged | 13 | 2025 | 18969 | 0.540 |
Why?
| | Prisons | 4 | 2021 | 72 | 0.540 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.530 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.530 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 16 | 0.530 |
Why?
| | Lymphocytosis | 1 | 2016 | 9 | 0.530 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 12 | 0.530 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 14 | 0.520 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 33 | 0.520 |
Why?
| | Occupational Diseases | 1 | 2017 | 128 | 0.520 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.510 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.510 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 179 | 0.510 |
Why?
| | Colombia | 4 | 2020 | 34 | 0.510 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 6 | 0.510 |
Why?
| | Insect Vectors | 1 | 2015 | 27 | 0.500 |
Why?
| | Gamma Rays | 1 | 2015 | 47 | 0.500 |
Why?
| | Plasma Cells | 1 | 2015 | 56 | 0.500 |
Why?
| | Transplants | 1 | 2015 | 36 | 0.490 |
Why?
| | Lymphoma | 1 | 2016 | 176 | 0.480 |
Why?
| | Anemia | 1 | 2016 | 143 | 0.480 |
Why?
| | Bone Marrow | 1 | 2016 | 243 | 0.470 |
Why?
| | Heart Ventricles | 1 | 2019 | 723 | 0.470 |
Why?
| | Environmental Exposure | 1 | 2018 | 372 | 0.470 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 397 | 0.460 |
Why?
| | Thrombocytopenia | 1 | 2016 | 177 | 0.460 |
Why?
| | Transplant Recipients | 1 | 2015 | 136 | 0.440 |
Why?
| | Research | 1 | 2016 | 389 | 0.430 |
Why?
| | Myocardial Contraction | 1 | 2015 | 318 | 0.430 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 192 | 0.430 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 3 | 0.420 |
Why?
| | Thrombocytosis | 1 | 2013 | 6 | 0.420 |
Why?
| | Betacoronavirus | 6 | 2020 | 247 | 0.420 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 14 | 0.420 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 61 | 0.410 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 19 | 0.410 |
Why?
| | Incidence | 3 | 2025 | 2314 | 0.410 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 10 | 0.400 |
Why?
| | Acinetobacter | 1 | 2012 | 13 | 0.400 |
Why?
| | Proctitis | 1 | 2012 | 5 | 0.400 |
Why?
| | Healthcare Disparities | 3 | 2024 | 479 | 0.400 |
Why?
| | Herpes Genitalis | 1 | 2012 | 16 | 0.400 |
Why?
| | H-2 Antigens | 1 | 2012 | 110 | 0.400 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 27 | 0.390 |
Why?
| | Cellulitis | 1 | 2012 | 45 | 0.390 |
Why?
| | Animals | 15 | 2024 | 31565 | 0.390 |
Why?
| | Isoxazoles | 1 | 2012 | 51 | 0.390 |
Why?
| | Treatment Outcome | 11 | 2024 | 9049 | 0.390 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 6 | 0.380 |
Why?
| | Severe Dengue | 1 | 2011 | 9 | 0.380 |
Why?
| | Acyclovir | 1 | 2012 | 100 | 0.380 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 138 | 0.380 |
Why?
| | Emigration and Immigration | 2 | 2022 | 45 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3039 | 0.370 |
Why?
| | B-Lymphocytes | 1 | 2016 | 762 | 0.370 |
Why?
| | Poliovirus | 2 | 2022 | 77 | 0.360 |
Why?
| | Pancreatitis | 1 | 2011 | 105 | 0.360 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2087 | 0.350 |
Why?
| | Young Adult | 9 | 2024 | 10444 | 0.350 |
Why?
| | Databases, Factual | 2 | 2025 | 1125 | 0.340 |
Why?
| | Repressor Proteins | 1 | 2013 | 367 | 0.340 |
Why?
| | Lung Diseases | 2 | 2018 | 690 | 0.340 |
Why?
| | Acute Lung Injury | 1 | 2013 | 268 | 0.340 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 2 | 0.340 |
Why?
| | Moraxella | 1 | 2009 | 5 | 0.340 |
Why?
| | Aged, 80 and over | 5 | 2024 | 6306 | 0.330 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1032 | 0.330 |
Why?
| | Lupus Nephritis | 1 | 2009 | 52 | 0.320 |
Why?
| | Fluconazole | 3 | 2023 | 16 | 0.320 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 49 | 0.320 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 267 | 0.310 |
Why?
| | Immunoglobulin G | 3 | 2023 | 766 | 0.310 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 340 | 0.310 |
Why?
| | Presenilin-1 | 1 | 2008 | 27 | 0.300 |
Why?
| | Fatal Outcome | 2 | 2019 | 281 | 0.300 |
Why?
| | Engineering | 1 | 2018 | 25 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1356 | 0.290 |
Why?
| | Social Responsibility | 1 | 2018 | 45 | 0.290 |
Why?
| | Public Health | 3 | 2020 | 433 | 0.280 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 67 | 0.280 |
Why?
| | Echinocandins | 2 | 2023 | 8 | 0.280 |
Why?
| | Mycobacterium | 2 | 2018 | 103 | 0.270 |
Why?
| | Antiviral Agents | 1 | 2012 | 642 | 0.270 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 637 | 0.270 |
Why?
| | Attitude | 1 | 2018 | 228 | 0.260 |
Why?
| | Sepsis | 2 | 2022 | 507 | 0.260 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 926 | 0.260 |
Why?
| | HIV | 2 | 2018 | 208 | 0.260 |
Why?
| | Electrocardiography | 2 | 2019 | 561 | 0.250 |
Why?
| | Propensity Score | 2 | 2023 | 225 | 0.250 |
Why?
| | Shock, Septic | 2 | 2021 | 185 | 0.250 |
Why?
| | Aminoglycosides | 1 | 2025 | 14 | 0.240 |
Why?
| | Erythromycin | 1 | 2025 | 25 | 0.240 |
Why?
| | Candida tropicalis | 1 | 2024 | 2 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 610 | 0.240 |
Why?
| | Angioedema | 1 | 2025 | 16 | 0.240 |
Why?
| | Cross Reactions | 1 | 2025 | 118 | 0.240 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 13 | 0.240 |
Why?
| | Colorado | 3 | 2020 | 4090 | 0.240 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.230 |
Why?
| | Alanine | 1 | 2024 | 105 | 0.220 |
Why?
| | Teicoplanin | 2 | 2023 | 17 | 0.220 |
Why?
| | Peru | 2 | 2024 | 54 | 0.220 |
Why?
| | World Health Organization | 2 | 2021 | 101 | 0.220 |
Why?
| | Toxoplasma | 1 | 2023 | 31 | 0.220 |
Why?
| | Toxoplasmosis | 1 | 2023 | 31 | 0.220 |
Why?
| | Meningoencephalitis | 1 | 2023 | 24 | 0.220 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1791 | 0.220 |
Why?
| | Voriconazole | 1 | 2023 | 24 | 0.220 |
Why?
| | Students | 1 | 2018 | 499 | 0.210 |
Why?
| | Pregnancy | 4 | 2024 | 5499 | 0.210 |
Why?
| | Pyridones | 1 | 2024 | 122 | 0.210 |
Why?
| | Rabies | 1 | 2022 | 1 | 0.210 |
Why?
| | Rabies Vaccines | 1 | 2022 | 2 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2272 | 0.210 |
Why?
| | Alzheimer Disease | 1 | 2008 | 442 | 0.210 |
Why?
| | Prognosis | 3 | 2022 | 3315 | 0.210 |
Why?
| | Tenofovir | 1 | 2024 | 204 | 0.210 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 3 | 0.210 |
Why?
| | Glycopeptides | 1 | 2023 | 43 | 0.210 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 813 | 0.200 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 949 | 0.200 |
Why?
| | Dog Diseases | 1 | 2022 | 41 | 0.200 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 154 | 0.200 |
Why?
| | Americas | 1 | 2022 | 17 | 0.200 |
Why?
| | Disease Notification | 1 | 2022 | 12 | 0.200 |
Why?
| | Rural Population | 2 | 2022 | 443 | 0.200 |
Why?
| | Italy | 1 | 2022 | 92 | 0.200 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.200 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 29 | 0.190 |
Why?
| | Leprosy | 1 | 2021 | 10 | 0.190 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1078 | 0.190 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 212 | 0.190 |
Why?
| | Population Dynamics | 1 | 2022 | 123 | 0.190 |
Why?
| | Case-Control Studies | 3 | 2018 | 3003 | 0.190 |
Why?
| | Weight Gain | 1 | 2024 | 453 | 0.180 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.180 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 7 | 0.180 |
Why?
| | Phosphorylcholine | 1 | 2020 | 17 | 0.180 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 12 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 445 | 0.180 |
Why?
| | Developing Countries | 1 | 2022 | 231 | 0.180 |
Why?
| | Pericarditis | 1 | 2020 | 9 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 50 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1128 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 34 | 0.170 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.170 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 138 | 0.170 |
Why?
| | Africa | 1 | 2020 | 92 | 0.170 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 641 | 0.170 |
Why?
| | Immunization, Secondary | 1 | 2020 | 82 | 0.170 |
Why?
| | Prospective Studies | 4 | 2023 | 6195 | 0.170 |
Why?
| | Late Onset Disorders | 1 | 2019 | 1 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2090 | 0.170 |
Why?
| | Proteinuria | 1 | 2020 | 77 | 0.170 |
Why?
| | Bolivia | 1 | 2019 | 62 | 0.170 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 61 | 0.170 |
Why?
| | Infection Control | 1 | 2021 | 132 | 0.160 |
Why?
| | Medical Errors | 1 | 2020 | 86 | 0.160 |
Why?
| | Neoplasms | 1 | 2013 | 2086 | 0.160 |
Why?
| | Acute Disease | 2 | 2012 | 907 | 0.160 |
Why?
| | Vulnerable Populations | 1 | 2020 | 129 | 0.160 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 90 | 0.160 |
Why?
| | Amphotericin B | 1 | 2019 | 28 | 0.160 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.160 |
Why?
| | Sex Factors | 1 | 2024 | 1706 | 0.160 |
Why?
| | Echocardiography | 2 | 2020 | 569 | 0.160 |
Why?
| | Dermatitis | 1 | 2018 | 17 | 0.160 |
Why?
| | Stroke Volume | 1 | 2021 | 513 | 0.160 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 222 | 0.160 |
Why?
| | Speech Disorders | 1 | 2018 | 30 | 0.160 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 100 | 0.160 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 107 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 6077 | 0.150 |
Why?
| | Respiration, Artificial | 1 | 2022 | 528 | 0.150 |
Why?
| | California | 1 | 2019 | 351 | 0.150 |
Why?
| | Africa, Western | 1 | 2018 | 16 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 122 | 0.150 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 477 | 0.150 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2384 | 0.150 |
Why?
| | Raw Foods | 1 | 2018 | 2 | 0.150 |
Why?
| | Administration, Oral | 2 | 2020 | 725 | 0.150 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 282 | 0.150 |
Why?
| | Prisoners | 1 | 2020 | 124 | 0.150 |
Why?
| | Itraconazole | 1 | 2017 | 7 | 0.150 |
Why?
| | Cytokines | 2 | 2022 | 1824 | 0.150 |
Why?
| | Food Microbiology | 1 | 2018 | 57 | 0.150 |
Why?
| | Georgia | 1 | 2017 | 62 | 0.150 |
Why?
| | Hyponatremia | 1 | 2018 | 37 | 0.150 |
Why?
| | Research Design | 2 | 2021 | 919 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2020 | 520 | 0.140 |
Why?
| | Patient Safety | 1 | 2020 | 273 | 0.140 |
Why?
| | Farmers | 1 | 2017 | 42 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 271 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 675 | 0.140 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1080 | 0.140 |
Why?
| | Brain | 1 | 2008 | 2355 | 0.130 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| | Albendazole | 1 | 2016 | 4 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2020 | 673 | 0.130 |
Why?
| | Pharmacists | 1 | 2019 | 231 | 0.130 |
Why?
| | Ivermectin | 1 | 2016 | 9 | 0.130 |
Why?
| | Vaccination | 2 | 2022 | 1202 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 239 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 662 | 0.130 |
Why?
| | Hematocrit | 1 | 2016 | 86 | 0.130 |
Why?
| | Mental Disorders | 1 | 2023 | 889 | 0.130 |
Why?
| | Hospitals, University | 1 | 2016 | 169 | 0.130 |
Why?
| | Arachis | 1 | 2017 | 146 | 0.130 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.130 |
Why?
| | Disease Outbreaks | 3 | 2023 | 305 | 0.130 |
Why?
| | Anthelmintics | 1 | 2015 | 8 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1331 | 0.130 |
Why?
| | Clone Cells | 1 | 2016 | 247 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 925 | 0.130 |
Why?
| | Genotype | 2 | 2012 | 1757 | 0.120 |
Why?
| | Lipids | 1 | 2019 | 564 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 405 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 82 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 124 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 381 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 116 | 0.120 |
Why?
| | Hearing Loss | 1 | 2018 | 183 | 0.120 |
Why?
| | Frontal Lobe | 1 | 2015 | 141 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 493 | 0.120 |
Why?
| | Biopsy | 2 | 2020 | 1024 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2020 | 670 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1422 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 308 | 0.110 |
Why?
| | Health Status Disparities | 3 | 2020 | 200 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 828 | 0.110 |
Why?
| | Disease Progression | 2 | 2012 | 2371 | 0.110 |
Why?
| | Child | 6 | 2023 | 18401 | 0.110 |
Why?
| | Feces | 1 | 2015 | 372 | 0.110 |
Why?
| | Parasite Load | 1 | 2013 | 7 | 0.110 |
Why?
| | APACHE | 1 | 2013 | 58 | 0.110 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 663 | 0.100 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.100 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 13 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 325 | 0.100 |
Why?
| | Klebsiella Infections | 1 | 2013 | 23 | 0.100 |
Why?
| | Logistic Models | 1 | 2018 | 1829 | 0.100 |
Why?
| | Comorbidity | 2 | 2022 | 1447 | 0.100 |
Why?
| | Platelet Count | 1 | 2013 | 79 | 0.100 |
Why?
| | Syncope | 1 | 2013 | 38 | 0.100 |
Why?
| | Molecular Typing | 1 | 2012 | 18 | 0.100 |
Why?
| | Clindamycin | 1 | 2012 | 12 | 0.100 |
Why?
| | Serratia Infections | 1 | 2012 | 6 | 0.100 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 245 | 0.100 |
Why?
| | Serratia marcescens | 1 | 2012 | 12 | 0.100 |
Why?
| | Central America | 2 | 2023 | 16 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 70 | 0.100 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1144 | 0.100 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 68 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 445 | 0.100 |
Why?
| | Disease Eradication | 2 | 2022 | 4 | 0.100 |
Why?
| | Viral Load | 2 | 2024 | 405 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 172 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2247 | 0.100 |
Why?
| | Microscopy | 1 | 2013 | 125 | 0.100 |
Why?
| | Blister | 1 | 2011 | 43 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 38 | 0.090 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 99 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 156 | 0.090 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 19 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 30 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 911 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 4402 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 74 | 0.090 |
Why?
| | Venezuela | 2 | 2021 | 7 | 0.090 |
Why?
| | Coinfection | 1 | 2012 | 120 | 0.090 |
Why?
| | Cohort Studies | 3 | 2022 | 4883 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2011 | 109 | 0.090 |
Why?
| | Mice | 3 | 2023 | 14843 | 0.090 |
Why?
| | Cross Infection | 1 | 2013 | 194 | 0.090 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 131 | 0.090 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 139 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1417 | 0.090 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 220 | 0.090 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 246 | 0.090 |
Why?
| | Hypertension | 1 | 2018 | 1052 | 0.080 |
Why?
| | Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| | Piperacillin | 1 | 2009 | 8 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 40 | 0.080 |
Why?
| | Debridement | 1 | 2009 | 71 | 0.080 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 173 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 219 | 0.080 |
Why?
| | Needs Assessment | 2 | 2021 | 315 | 0.080 |
Why?
| | Mortality | 2 | 2021 | 283 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 370 | 0.080 |
Why?
| | Genes, Dominant | 1 | 2008 | 93 | 0.080 |
Why?
| | Socialization | 1 | 2018 | 22 | 0.070 |
Why?
| | Global Health | 2 | 2020 | 284 | 0.070 |
Why?
| | Chromosome Disorders | 1 | 2008 | 35 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2023 | 614 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 216 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 261 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 320 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 460 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 373 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 476 | 0.070 |
Why?
| | Chronic Disease | 1 | 2012 | 1577 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 489 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2012 | 787 | 0.060 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 189 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2322 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2018 | 575 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 674 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 4680 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 381 | 0.060 |
Why?
| | Registries | 1 | 2013 | 1764 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 913 | 0.060 |
Why?
| | Adolescent | 4 | 2023 | 17800 | 0.060 |
Why?
| | Moths | 1 | 2024 | 34 | 0.060 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 665 | 0.060 |
Why?
| | Antivenins | 1 | 2024 | 56 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 46 | 0.060 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 30 | 0.060 |
Why?
| | Acetazolamide | 1 | 2023 | 30 | 0.060 |
Why?
| | Human Rights | 1 | 2023 | 15 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 137 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 62 | 0.050 |
Why?
| | Panama | 1 | 2022 | 9 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 125 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3498 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 22 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 3 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 12 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 62 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 4595 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2629 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 22 | 0.050 |
Why?
| | Adenine | 1 | 2024 | 218 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 245 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 256 | 0.050 |
Why?
| | Mexico | 1 | 2022 | 162 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1875 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 75 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 300 | 0.050 |
Why?
| | Curriculum | 1 | 2018 | 813 | 0.050 |
Why?
| | Cameroon | 1 | 2021 | 8 | 0.050 |
Why?
| | Cuba | 1 | 2021 | 11 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 14 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 331 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 191 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2022 | 169 | 0.050 |
Why?
| | Inflammation | 2 | 2022 | 2464 | 0.050 |
Why?
| | Minority Health | 1 | 2021 | 19 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 223 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 285 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 156 | 0.040 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 2 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
| | History, 17th Century | 1 | 2020 | 15 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 600 | 0.040 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 67 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 4501 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 325 | 0.040 |
Why?
| | Network Meta-Analysis | 1 | 2020 | 12 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 36 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 89 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 80 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 67 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 61 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 136 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 385 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 160 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 106 | 0.040 |
Why?
| | Cough | 1 | 2020 | 107 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 265 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 30 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 138 | 0.040 |
Why?
| | HIV-1 | 1 | 2024 | 768 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 121 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 89 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 308 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2020 | 183 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2020 | 274 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2020 | 217 | 0.040 |
Why?
| | Critical Illness | 1 | 2023 | 640 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2020 | 159 | 0.040 |
Why?
| | Urban Population | 1 | 2020 | 396 | 0.040 |
Why?
| | Risk | 1 | 2020 | 810 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 990 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 255 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 581 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2020 | 513 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 979 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 660 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3254 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 17 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 62 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2958 | 0.020 |
Why?
| | Infant | 1 | 2021 | 7943 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 9114 | 0.020 |
Why?
| | Lung | 1 | 2020 | 3521 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1836 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|